<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2018-5-27-33</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-2695</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>ВЗАИМОСВЯЗЬ ФАКТОРОВ ВОСПАЛЕНИЯ И МЕТАБОЛИЧЕСКИХ ПАРАМЕТРОВ ПРИ ОЖИРЕНИИ У ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ ГИПЕРТОНИЕЙ ВЫСОКОГО И ОЧЕНЬ ВЫСОКОГО РИСКА</article-title><trans-title-group xml:lang="en"><trans-title>INTERPLAY OF INFLAMMATION AND METABOLIC FACTORS IN COMORBID OBESITY AND ARTERIAL HYPERTENSION OF HIGH AND VERY HIGH RISK</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4537-0008</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кологривова</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kologrivova</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ирина Вячеславовна Кологривова — кандидат медицинских наук, научный сотрудник, отделение функциональной и лабораторной диагностики </p><p>Томск</p></bio><bio xml:lang="en"/><email xlink:type="simple">ikologrivova@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6679-1269</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кошельская</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Koshelskaya</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Доктор медицинских наук, профессор, ведущий научный сотрудник, отделение атеросклероза и хронической ишемической болезни сердца </p><p>Томск</p></bio><bio xml:lang="en"/><email xlink:type="simple">koshel@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9645-6720</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Суслова</surname><given-names>Т. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Suslova</surname><given-names>T. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандидат медицинских наук, научный сотрудник, отделение функциональной и лабораторной диагностики </p><p>Томск</p></bio><bio xml:lang="en"/><email xlink:type="simple">tes@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6489-0650</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Винницкая</surname><given-names>И. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Vinnitskaya</surname><given-names>I. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Научный сотрудник, отделение атеросклероза и хронической ишемической болезни сердца </p><p>Томск</p></bio><bio xml:lang="en"/><email xlink:type="simple">airinvin82@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1235-9956</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кравченко</surname><given-names>Е. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kravchenko</surname><given-names>E. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Младший научный сотрудник, отделение функциональной и лабораторной диагностики </p><p>Томск</p></bio><bio xml:lang="en"/><email xlink:type="simple">Nikonova@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1253-3352</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Трубачева</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Trubacheva</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кандидат медицинских наук, научный сотрудник, отделение функциональной и лабораторной диагностики </p><p>Томск</p></bio><bio xml:lang="en"/><email xlink:type="simple">OATrubacheva@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Научно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наук<country>Россия</country></aff><aff xml:lang="en">Scientific-Research Institute of Cardiology, Tomsk National Research Medical Center of RAS<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>02</day><month>06</month><year>2018</year></pub-date><volume>0</volume><issue>5</issue><fpage>27</fpage><lpage>33</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кологривова И.В., Кошельская О.А., Суслова Т.Е., Винницкая И.В., Кравченко Е.С., Трубачева О.А., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Кологривова И.В., Кошельская О.А., Суслова Т.Е., Винницкая И.В., Кравченко Е.С., Трубачева О.А.</copyright-holder><copyright-holder xml:lang="en">Kologrivova I.V., Koshelskaya O.A., Suslova T.E., Vinnitskaya I.V., Kravchenko E.S., Trubacheva O.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/2695">https://russjcardiol.elpub.ru/jour/article/view/2695</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучение содержания FoxP3+ Т-регуляторных лимфоцитов (Treg) при избыточной массе тела и ожирении у пациентов с артериальной гипертензией (АГ) высокого и очень высокого риска, и взаимосвязи содержания Treg с параметрами обмена углеводов и липидов.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Было проведено одномоментное поперечное исследование, в которое вошли 39 пациентов с АГ высокого и очень высокого сердечно-сосудистого риска с антропометрическими признаками избыточной массы тела и ожирения 1 степени. Для идентификации Treg определяли внутриклеточную экспрессию транскрипционного фактора FoxP3. В сыворотке крови определяли содержание С-реактивного белка высокочувствительным методом ^СРБ), лептина, адипонектина, параметры липидного и углеводного обмена.</p></sec><sec><title>Результаты</title><p>Результаты. По данным ROC-анализа, содержание FoxP3+ Treg менее 3,18% позволяет идентифицировать пациентов с концентрацией hsСРБ &gt;3 мг/л (чувствительность определения — 74%; специфичность — 68%).</p><p>Были выделены подгруппы, различающиеся по содержанию FoxP3+ Т-регуляторных лимфоцитов (подгруппа 1: пациенты с уровнем FoxP3+ Treg &lt;3,18%; подгруппа 2: пациенты с уровнем FoxP3+ Treg &gt;3,18%). У пациентов подгруппы 1 была выявлена прямая взаимосвязь между содержанием FoxP3+ Treg-лимфоцитов и ХС-ЛВП (Rs=0,564; p=0,012). Женщины подгруппы 1 характеризовались большей окружностью талии по сравнению с женщинами в подгруппе 2 (р=0,025), тогда как у мужчин обеих подгрупп различия по окружности талии отсутствовали. В подгруппе 1 пациентымужчины характеризовались более низким содержанием ХС-ЛВП по сравнению с женщинами (р=0,005), однако, эти различия отсутствовали в подгруппе пациентов с содержанием FoxP3+ Treg &gt;3,18%. Среди пациентов подгруппы 2 содержание FoxP3+ Treg у мужчин проявляло тенденцию к более высоким значениям, в сравнении с женщинами.</p></sec><sec><title>Заключение</title><p>Заключение. У пациентов с АГ высокого и очень высокого риска при наличии избыточной массы тела и ожирения 1-й степени впервые установлена ассоциация между содержанием Treg-лимфоцитов и концентрацией ЛВП, что реализуется в случае выраженной активации процессов субклинического воспаления. Обнаружены гендерные особенности потенциальных механизмов увеличения содержания FoxP3+ Treg-лимфоцитов. Выявленные в нашем исследовании взаимосвязи обосновывают возможность разработки новых подходов к стратификации кардиометаболического риска.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. Evaluation of the FoxP3+ T-regulatory lymphocytes (Treg) content in overweight and obesity in arterial hypertension (AH) patients of high and very high risk, and relation of Treg amount with the parameters of lipid and carbohydrate metabolism.</p></sec><sec><title>Material and methods</title><p>Material and methods. A momentary cross sectional study was done, that included 39 patients with AH of high and very high cardiovascular risk with anthropometric signs of overweight and grade 1 obesity. For identification of Treg, intracellular expression of FoxP3 transcriptional factor was assessed. In the blood serum, high sensitive C-reactive protein (hsCRP) was measured, with leptin, adiponectin, parameters of lipid and carbohydrate metabolism.</p></sec><sec><title>Results</title><p>Results. By the ROC-analysis, the content of FoxP3+ Treg below 3,18% makes it to identify patients with hsCRP &gt;3 mg/L (sensitivity — 74%; specificity — 68%). Subgroups were selected that differ by the content of FoxP3+ of T-regulatory lymphocytes (subgroup 1: patients with the level of FoxP3+ Treg &lt;3,18%; subgroup 2: patients with FoxP3+ Treg &gt;3,18%). In subgroup 1 patients there was direct correlation revelaed of FoxP3+ Treg-lymphocytes content and HDL cholesterol (Rs=0,564; p=0,012). Females of subgroup 1 were characterized by higher waist circumference comparing to the females of subgroup 2 (p=0,025); in males, however, there were no differences in waist circumference. In subgroup 1 male patients were characterized by lower HDL cholesterol comparing to women (p=0,005), however such difference was absent in the subgroup of patients with FoxP3+ Treg &gt;3,18%. Among the patients of subgroup 2 the content of FoxP3+ Treg in males showed tendency to higher values comparing with females.</p></sec><sec><title>Conclusion</title><p>Conclusion. In AH patients of high and very high risk, overweight and obesity grade 1, first time an association revealed of Treg lymphocytes and HDL concentration, that is related to higher rate of subclinical inflammation. Gender specifics is found for potential mechanisms of increase of FoxP3+ Treg-lymphocytes. The relations that revealed in our study underscore an opportunity to develop novel approaches to cardiometabolic risk stratification.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>ожирение</kwd><kwd>FoxP3+ Т-регуляторные лимфоциты</kwd><kwd>липопротеины высокой плотности</kwd><kwd>C-реактивный белок</kwd><kwd>гендерные различия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>obesity</kwd><kwd>FoxP3+ T-regulatory lymphocytes</kwd><kwd>high density lipoproteines</kwd><kwd>C-reactive protein</kwd><kwd>gender difference</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>ФАНО России</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Wagner N-M, Brandhorst G, Czepluch F, et al. Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk. Obesity. 2013; 21 (3): 461-8. DOI: 10.1002/oby.20087.</mixed-citation><mixed-citation xml:lang="en">Wagner N-M, Brandhorst G, Czepluch F, et al. Circulating regulatory T cells are reduced in obesity and may identify subjects at increased metabolic and cardiovascular risk. Obesity. 2013; 21 (3): 461-8. DOI: 10.1002/oby.20087.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Feuerer M, Herrero L, Cipoletta D, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nature Med. 2009; 15: 930-9. DOI: 10.1038/nm.2002.</mixed-citation><mixed-citation xml:lang="en">Feuerer M, Herrero L, Cipoletta D, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nature Med. 2009; 15: 930-9. DOI: 10.1038/nm.2002.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Mancia G, Fagard R, Narkiewicz K. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31 (7): 1281-357. DOI: 10.1097/01.hjh.0000431740.32696.cc.</mixed-citation><mixed-citation xml:lang="en">Mancia G, Fagard R, Narkiewicz K. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31 (7): 1281-357. DOI: 10.1097/01.hjh.0000431740.32696.cc.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Yousuf O, Mohanty BD, Martin SS, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013; 62 (5): 397-408. DOI: 10.1016/j.jacc.2013.05.016.</mixed-citation><mixed-citation xml:lang="en">Yousuf O, Mohanty BD, Martin SS, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol. 2013; 62 (5): 397-408. DOI: 10.1016/j.jacc.2013.05.016.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Newton R, Priyadharshini B, Turka LA. Immunometabolism of regulatory T cells. Nat Immunol. 2016; 17 (6): 618-25. DOI:10.1038/ni.3466.</mixed-citation><mixed-citation xml:lang="en">Newton R, Priyadharshini B, Turka LA. Immunometabolism of regulatory T cells. Nat Immunol. 2016; 17 (6): 618-25. DOI:10.1038/ni.3466.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Emoto T, Sasaki N, Yamashita T. Regulatory/effector T-cell ratio is reduced in coronary artery disease. Circ J. 2014; 78: 2935-41. DOI: 10.1253/circj.CJ-14-0644.</mixed-citation><mixed-citation xml:lang="en">Emoto T, Sasaki N, Yamashita T. Regulatory/effector T-cell ratio is reduced in coronary artery disease. Circ J. 2014; 78: 2935-41. DOI: 10.1253/circj.CJ-14-0644.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-7. DOI: 10.1038/nature05485.</mixed-citation><mixed-citation xml:lang="en">Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-7. DOI: 10.1038/nature05485.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">De Rosa V, Procaccini C, Call G, et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity. 2007; 26 (2): 241-55. DOI: 10.1016/j.immuni.2007.01.011.</mixed-citation><mixed-citation xml:lang="en">De Rosa V, Procaccini C, Call G, et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity. 2007; 26 (2): 241-55. DOI: 10.1016/j.immuni.2007.01.011.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Rueda CM, Rodrlguez-Perea AL, Moreno-Fernandez M, et al. High density lipoproteins selectively promote the survival of human regulatory T cells. J Lipid Res. 2017; 58 (8): 1514-23. DOI: 10.1194/jlr.M072835.</mixed-citation><mixed-citation xml:lang="en">Rueda CM, Rodrlguez-Perea AL, Moreno-Fernandez M, et al. High density lipoproteins selectively promote the survival of human regulatory T cells. J Lipid Res. 2017; 58 (8): 1514-23. DOI: 10.1194/jlr.M072835.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Liu G, Yang K, Burns S, et al. S1P1-mTOR axis directs the reciprocal differentiation of TH1 and regulatory T cells. Nat Immunol. 2010; 11 (11): 1047-56. DOI: 10.1038/ni.1939.</mixed-citation><mixed-citation xml:lang="en">Liu G, Yang K, Burns S, et al. S1P1-mTOR axis directs the reciprocal differentiation of TH1 and regulatory T cells. Nat Immunol. 2010; 11 (11): 1047-56. DOI: 10.1038/ni.1939.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Mahdy Ali K, Wonnerth A, Huber K, et al. Cardiovascular disease risk reduction by raising HDL cholesterol — current therapies and future opportunities. Br J Pharmacol. 2012; 167 (6): 1177-94. DOI: 10.1111/j.1476-5381.2012.02081.x.</mixed-citation><mixed-citation xml:lang="en">Mahdy Ali K, Wonnerth A, Huber K, et al. Cardiovascular disease risk reduction by raising HDL cholesterol — current therapies and future opportunities. Br J Pharmacol. 2012; 167 (6): 1177-94. DOI: 10.1111/j.1476-5381.2012.02081.x.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Nie J, Li YY, Zheng SG, et al. FOXP3+ Treg Cells and Gender Bias in Autoimmune Diseases. Front Immunol. 2015; 6: 493. DOI: 10.3389/fimmu.2015.00493.</mixed-citation><mixed-citation xml:lang="en">Nie J, Li YY, Zheng SG, et al. FOXP3+ Treg Cells and Gender Bias in Autoimmune Diseases. Front Immunol. 2015; 6: 493. DOI: 10.3389/fimmu.2015.00493.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Кологривова И.В., Винницкая И. В., Кошельская О. А. и др. Висцеральное ожирение и кардиометаболический риск: особенности гормональное и иммунной регуляции. Ожирение и метаболизм. 2017; 14 (3): 3-10. DOI: http://dx.doi.org/10.14341/omet201733-10.</mixed-citation><mixed-citation xml:lang="en">Kologrivova IV, Vinnitskaya IV, Koshelskaya OA, et al. Visceral obesity and cardiometabolic risk: features of hormonal and immune regulation. Obesity and metabolism. 2017; 14 (3): 3-10. (In Russ.) https://doi.org/http://dx.doi.org/10.14341/omet201733-10.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
